Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among […]
More Stories
Mizuho Issues Pessimistic Forecast for EOG Resources (NYSE:EOG) Stock Price
EOG Resources (NYSE:EOG – Get Free Report) had its target price dropped by research analysts at Mizuho from $156.00 to...
THORChain (RUNE) Price Tops $6.37 on Exchanges
THORChain (RUNE) traded 0.8% higher against the dollar during the one day period ending at 8:00 AM ET on December...
Bank of America Downgrades Credicorp (NYSE:BAP) to Neutral
Credicorp (NYSE:BAP – Get Free Report) was downgraded by stock analysts at Bank of America from a “buy” rating to...
Ambarella, Inc. (NASDAQ:AMBA) Short Interest Update
Ambarella, Inc. (NASDAQ:AMBA – Get Free Report) was the recipient of a significant increase in short interest in the month...
Macquarie Initiates Coverage on Pediatrix Medical Group (NYSE:MD)
Equities researchers at Macquarie began coverage on shares of Pediatrix Medical Group (NYSE:MD – Get Free Report) in a research...
Critical Survey: AEON Biopharma (AEON) vs. Its Rivals
AEON Biopharma (NASDAQ:AEON – Get Free Report) is one of 1,059 publicly-traded companies in the “Pharmaceutical preparations” industry, but how...